Beijing Leader Bio-Science Co., Ltd. announced that its subsidiary, Beijing Sci-Nature Gene Bio-Products Co., Ltd., has received approval from the NMPA for the clinical trial of its recombinant B meningococcal vaccine (E. coli). This marks a significant step in the development of a vaccine to prevent meningococcal meningitis caused by Neisseria meningitidis serogroup B.
Summary generated by AI · Always verify with source document
Stock Code: 300289
Stock Abbreviation: Leader Bio-Science
Announcement No.: 2026-050
Beijing Leader Bio-Science Co., Ltd.
Announcement on Subsidiary's Recombinant B Meningococcal Vaccine (E. coli) Obtaining Clinical Trial Approval Notice
The Company and the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and do not contain any false records, misleading statements, or major omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.